KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC

May 29-June 2, 2015; Chicago, Illinois
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.
Format: Microsoft PowerPoint (.ppt)
File Size: 423 KB
Released: June 1, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

CME-certified Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 20, 2019 Expiration: November 19, 2020

In this slideset, experts provide insights on immunotherapy use for stage III NSCLC today and emerging developments in this setting and earlier stages of NSCLC.

Roy S. Herbst, MD, PhD Melissa L. Johnson, MD Released: November 8, 2019

In this slideset, Sanjay Mukhopadhyay, MD, reviews biomarker testing in lung cancer, including molecular testing by NGS and PD-L1 testing to predict response to checkpoint inhibitors.

Sanjay Mukhopadhyay, MD Released: November 5, 2019

In this slideset, Joshua Bauml, MD; Sandip P. Patel, MD; and H. Jack West, MD, review the latest clinical data supporting the optimal use of biomarker testing for checkpoint inhibitor therapy across lung cancer.

H. Jack West, MD
Program Director
Joshua Bauml, MD Sandip P. Patel, MD
Released: November 5, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?